Journal of Neurology

, Volume 259, Issue 2, pp 284–291

Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study


  • Thomas Meier
    • Santhera Pharmaceuticals
  • Susan L. Perlman
    • Department of NeurologyDavid Geffen School of Medicine at the University of California at Los Angeles
  • Christian Rummey
    • Santhera Pharmaceuticals
  • Nicholas J. Coppard
    • Santhera Pharmaceuticals
    • Division of NeurologyThe Children’s Hospital of Philadelphia
Original Communication

DOI: 10.1007/s00415-011-6174-y

Cite this article as:
Meier, T., Perlman, S.L., Rummey, C. et al. J Neurol (2012) 259: 284. doi:10.1007/s00415-011-6174-y


The aim of this study was to investigate the efficacy of idebenone on neurological function as assessed by ICARS and FARS neurological rating scales in pediatric Friedreich's ataxia (FRDA) patients. Sixty-eight pediatric patients were enrolled in an open-label extension study (IONIA-E) where patients received idebenone (Catena®, 150 mg film-coated tablets) at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months after patients had completed a double-blind, randomized, placebo-controlled study (IONIA) receiving either idebenone at a weight-adjusted dose of 450/900 or 1,350/2,250 mg/day or placebo for 6 months. Changes in ICARS and FARS total scores and subscores were recorded for the 12-month IONIA-E study and for the 18-month combined IONIA and IONIA-E study period. Data analyzed by a mixed-model repeated-measures ANCOVA relative to baseline resulted in least square means for the change in ICARS for the IONIA-E study of +0.98 points (SEM 0.73; p = 0.180), indicating a trend for worsening. However, combined with the IONIA study the change was −1.03 ± 0.68 points (p = 0.132), indicating a trend for improvement in neurological function over the 18-month period. Importantly, patients who received idebenone 1,350/2,250 mg/day over this period significantly improved in neurological function (change in ICARS: −3.02 ± 1.22, p = 0.014). The improvement in neurological function over time was best seen when the posture and stance subscore was excluded from the analysis. Comparable data were obtained with the FARS. The findings of the open-label IONIA-E study combined with the double-blind IONIA study indicate that idebenone at a dose of 1,350/2,250 mg/day may offer a therapeutic benefit to pediatric FRDA patients by stabilizing the overall neurological function and improving fine motor skills and speech.


Ataxia International Cooperative Ataxia Rating Scale Idebenone Movement disorder

Supplementary material

415_2011_6174_MOESM1_ESM.doc (36 kb)
Supplementary material 1 (DOC 36 kb)

Copyright information

© Springer-Verlag 2011